VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for Wonderland, the world-leading academic and business gathering in the psychedelic medicine industry…


Previous articleBexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit
Next articleReunion Neuroscience Inc. to Participate in Upcoming Investor Conferences